Literature DB >> 10207009

MAGUIN, a novel neuronal membrane-associated guanylate kinase-interacting protein.

I Yao1, Y Hata, N Ide, K Hirao, M Deguchi, H Nishioka, A Mizoguchi, Y Takai.   

Abstract

Postsynaptic density (PSD)-95/Synapse-associated protein (SAP) 90 and synaptic scaffolding molecule (S-SCAM) are neuronal membrane-associated guanylate kinases. Because PSD-95/SAP90 and S-SCAM function as synaptic scaffolding proteins, identification of ligands for these proteins is important to elucidate the structure of synaptic junctions. Here, we report a novel protein interacting with the PDZ domains of PSD-95/SAP90 and S-SCAM and named it MAGUIN-1 (membrane-associated guanylate kinase-interacting protein-1). MAGUIN-1 has one sterile alpha motif, one PDZ, and one plekstrin homology domain. MAGUIN-1 is localized at the plasma membrane via the plekstrin homology domain and the C-terminal region and interacts with PSD-95/SAP90 and S-SCAM via a C-terminal PDZ domain-binding motif. MAGUIN-1 has a short isoform, MAGUIN-2, which lacks a PDZ domain-binding motif. MAGUINs are expressed in neurons and localized in the cell body and neurites and are coimmunoprecipitated with PSD-95/SAP90 and S-SCAM from rat crude synaptosome. MAGUIN-1 may play an important role with PSD-95/SAP90 and S-SCAM to assemble the components of synaptic junctions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207009     DOI: 10.1074/jbc.274.17.11889

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Fbxo45, a novel ubiquitin ligase, regulates synaptic activity.

Authors:  Hirobumi Tada; Hirotaka James Okano; Hiroshi Takagi; Shinsuke Shibata; Ikuko Yao; Masaki Matsumoto; Toru Saiga; Keiichi I Nakayama; Haruo Kashima; Takuya Takahashi; Mitsutoshi Setou; Hideyuki Okano
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

2.  Interaction of synaptic scaffolding molecule and Beta -catenin.

Authors:  Wataru Nishimura; Ikuko Yao; Junko Iida; Noriaki Tanaka; Yutaka Hata
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

3.  Molecular architecture of postsynaptic Interactomes.

Authors:  Brent Wilkinson; Marcelo P Coba
Journal:  Cell Signal       Date:  2020-09-14       Impact factor: 4.315

4.  Loss-of-Function CNKSR2 Mutation Is a Likely Cause of Non-Syndromic X-Linked Intellectual Disability.

Authors:  G Houge; I H Rasmussen; R Hovland
Journal:  Mol Syndromol       Date:  2011-12-20

5.  The CNK1 scaffold binds cytohesins and promotes insulin pathway signaling.

Authors:  Junghwa Lim; Ming Zhou; Timothy D Veenstra; Deborah K Morrison
Journal:  Genes Dev       Date:  2010-07-15       Impact factor: 11.361

6.  The CNK2 scaffold interacts with vilse and modulates Rac cycling during spine morphogenesis in hippocampal neurons.

Authors:  Junghwa Lim; Daniel A Ritt; Ming Zhou; Deborah K Morrison
Journal:  Curr Biol       Date:  2014-03-20       Impact factor: 10.834

7.  Synaptic and nuclear localization of brain-enriched guanylate kinase-associated protein.

Authors:  Ikuko Yao; Junko Iida; Wataru Nishimura; Yutaka Hata
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

8.  Human CNK1 acts as a scaffold protein, linking Rho and Ras signal transduction pathways.

Authors:  Aron B Jaffe; Pontus Aspenström; Alan Hall
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

9.  Synaptic E3 ligase SCRAPPER in contextual fear conditioning: extensive behavioral phenotyping of Scrapper heterozygote and overexpressing mutant mice.

Authors:  Ikuko Yao; Keizo Takao; Tsuyoshi Miyakawa; Seiji Ito; Mitsutoshi Setou
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

10.  X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes.

Authors:  H Hu; S A Haas; J Chelly; H Van Esch; M Raynaud; A P M de Brouwer; S Weinert; G Froyen; S G M Frints; F Laumonnier; T Zemojtel; M I Love; H Richard; A-K Emde; M Bienek; C Jensen; M Hambrock; U Fischer; C Langnick; M Feldkamp; W Wissink-Lindhout; N Lebrun; L Castelnau; J Rucci; R Montjean; O Dorseuil; P Billuart; T Stuhlmann; M Shaw; M A Corbett; A Gardner; S Willis-Owen; C Tan; K L Friend; S Belet; K E P van Roozendaal; M Jimenez-Pocquet; M-P Moizard; N Ronce; R Sun; S O'Keeffe; R Chenna; A van Bömmel; J Göke; A Hackett; M Field; L Christie; J Boyle; E Haan; J Nelson; G Turner; G Baynam; G Gillessen-Kaesbach; U Müller; D Steinberger; B Budny; M Badura-Stronka; A Latos-Bieleńska; L B Ousager; P Wieacker; G Rodríguez Criado; M-L Bondeson; G Annerén; A Dufke; M Cohen; L Van Maldergem; C Vincent-Delorme; B Echenne; B Simon-Bouy; T Kleefstra; M Willemsen; J-P Fryns; K Devriendt; R Ullmann; M Vingron; K Wrogemann; T F Wienker; A Tzschach; H van Bokhoven; J Gecz; T J Jentsch; W Chen; H-H Ropers; V M Kalscheuer
Journal:  Mol Psychiatry       Date:  2015-02-03       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.